Introduction
Met, the receptor for hepatocyte growth factor (HGF) is a transmembrane tyrosine kinase mediating multiple biological functions such as cell proliferation, survival, motility, and invasion of extracellular matrices (Weidner et al., 1993; Medico et al., 1996; Bardelli et al., 1996; Fan et al., 1998) . It is involved in development (Schmidt et al., 1995; Bladt et al., 1995; Maina et al., 1996) and organ regeneration (Matsumoto and Nakamura, 1996) . The MET sequence was originally identi®ed as the cellular counterpart of a transforming gene, TPR-MET (Cooper et al., 1984; Park et al., 1986) . In Tpr-Met, the extracellular domain of Met is replaced by Tpr sequences, which provide two strong dimerization motifs (Rodrigues and Park, 1993) . Dimerization activates the Met kinase, which acquires transforming and metastatic properties (Park et al., 1986; Giordano et al., 1997) . The TPR-MET rearrangement is not often found in naturally occurring tumors, but MET is over-expressed, ampli®ed and activated by autocrine loop in a variety of human cancers (reviewed in Bardelli et al., 1997) .
A direct genetic link between MET and human cancer has been established by the identi®cation of germ-line and somatic mutations in the MET gene in papillary renal carcinomas (PRC; Schmidt et al., 1997 Schmidt et al., , 1999 and childhood hepatocellular carcinomas (HCC; Park et al., 1999) . All mutations are located in the kinase domain, either in the N-terminal lobe, which includes the ATP binding site, or in the Cterminal lobe, which includes the catalytic and activation loops. All of them seem to be activating, albeit to dierent degrees (Jeers et al., 1997; Bardelli et al., 1998) .
Two of these mutations are noteworthy (M1268T and D1246H/N), since they involve aminoacids highly conserved among receptor tyrosine kinases (RTKs). Homologous residues were previously found mutated in tumorigenic versions of the Ret and Kit receptors. The Ret M918T mutation is responsible for most cases of multiple endocrine neoplasia type 2B (MEN2B, reviewed by van Heyningen, 1994) . The Kit D816Y/V mutation is responsible for systemic mastocytosis in man, mouse and rat (Furitsu et al., 1993; Tsujimura et al., , 1995 . In Met, D1246 can be converted to either H or N. Conserved aminoacids in the tyrosine kinase domain may represent`hot spots' for activation in RTKs. Understanding the molecular basis for their activating eect may thus be of general interest.
The oncogenicity of these mutations may derive from a shift in substrate speci®city (Liu et al., 1996; Piao et al., 1996) . The aminoacids involved (M and D) are speci®c for receptor tyrosine kinases and are converted into residues typical of cytoplasmic tyrosine kinases. In the Met receptor, however, these mutations are among the most eective in inducing phosphorylation of the molecule. The two mutated residues are either in the in the P+1 loop (M1268) or within the A-loop (D1246), which are involved, respectively, in substrate recognition and kinase auto-inhibition. In RTKs the A-loop contains between one and three tyrosines whose ligandinduced phosphorylation is critical for shifting the kinase into an active form (Hubbard, 1997; Hubbard et al., 1998; Weiss and Schlessinger, 1998) . In Met, Y?F mutation of the tandem A-loop tyrosines Y1252-1253 yields an inactive kinase and abolishes all biological responses to HGF (Longati et al., 1994) . It also abrogates the transforming ability of Tpr-Met, the oncogenic counterpart of the receptor .
It has been hypothesized that the M1268T and D1246H/N mutations may facilitate transition to the active form of Met (Jeers et al., 1997; Schmidt et al., 1999) . However a precise understanding of their eect is lacking.
Another issue still open is the dependency of the M1268T and D1246H/N Met mutants on ligandinduced dimerization for activation. Although early reports described these and other tumorigenic Met mutants as constitutively activated, the same authors later showed that their activity can be further enhanced through ligand stimulation (Jeers et al., 1998a) . More recently, all mutant forms of Met were found to be not only sensitive to, but entirely dependent on the presence of the HGF ligand (Michieli et al., 1999) . The early results could be due to the use of HGFsecreting NIH3T3 cells.
This work was designed to assess the role of the M1268T and D1246H/N mutations in altering the conformation of the A-loop, and to further explore their dependency on receptor dimerization. To this end, we studied their eect in the Met kinase by themselves, or in combination with Y?F mutations of the A-loop tyrosines. The mutations were tested within a context of full dimerization (Tpr-Met) or in a dimerization-free context (Cyto-Met, corresponding to the isolated cytoplasmic Met moiety of Tpr-Met).
The results indicate that the M1268T mutation partially rescues the activity of the Y1252-1253F Met kinase, but is completely dependent on dimerization for its activating eect. Conversely, the D1246H/N mutant shows an absolute requirement for the two tyrosines in the A-loop, but its dependency on the ligand is reduced. Finally, the mechanism underlying the eect of the D1246H/N mutation seems to be shared by all A-loop mutations.
Results

Construction of Met mutants
The M1268T mutation and the D1246H/N mutations were introduced by site-directed mutagenesis in TprMet and Cyto-Met (the cytoplasmic Met moiety of Tpr-Met) by themselves, or in combination with Y?F mutations of the A-loop tyrosines Y1252-1253. The mutations were also introduced in the full-size receptor. A D?V version of the D1246 mutation (reproducing the substitution found in human Kit in mastocytosis) was also tested in Met, in addition to the naturally occurring D?H and D?N mutations. This was done to verify whether activation was related not only to the loss of a conserved acidic residue (D) but also to the acquisition of a speci®c residue in the Met versus the Kit kinase. Table 1 illustrates all constructs used in this work. Figure 1 illustrates the phosphorylation state of Figure 1 Schematic representation of dierent Met forms used in this work. The wild type full-size receptor is monomeric and unphosphorylated in the absence of the ligand. Binding with HGF promotes receptor dimerization and phosphorylation of the tandem tyrosines in the A-loop (Ferracini et al., 1991) and of the two carboxy-terminal tyrosines essential for signal transduction (Ponzetto et al., 1994; Zhu et al., 1994) . Two leucine zippers in Tpr promote constitutive dimerization and phosphorylation of the hybrid Tpr-Met molecule (Rodrigues and Park, 1993) . The truncated cytoplasmic kinase domain of Met (Cyto-Met) is monomeric and unphosphorylated The M1268T (but not the D1246H/N) mutation partially rescues the activity of the Y1252-1253F Tpr-Met kinase Figure 2 and Table 2 show the results obtained by testing the M1268T and the D1246H/N mutations (alone or in combination with the Y?F substitutions of the A-loop tyrosines) within the fully dimerized chimeric Tpr-Met molecule.
The upper part of Figure 2a shows the in vitro autokinase activity of the various Tpr-Met mutants after immuno-precipitation from transfected COS-1 cells. Introduction of the M1268T and D1246H/N mutations by themselves did not signi®cantly alter the auto-kinase activity of Tpr-Met (lanes 2, 4, 6, 8, 10). As expected, auto-phosphorylation was almost completely suppressed by Y?F mutation of the A-loop tyrosines (lanes 3, 5, 7, 9, 11), which are the major phosphorylation sites in the Met receptor (Ferracini et al., 1991) . On the other hand, when the same constructs were tested for their ability to transphosphorylate an exogenous substrate such as myelin basic protein (MBP), the M1268T (but not by the D1246H/N) mutation rescued in part the activity of the Y?F Tpr-Met mutant (lanes 5, 7, 9, 11 in Figure 2b ). The lower parts of Figure 2a ,b show that the kinase assays were done using extracts containing comparable amounts of Tpr-Met protein.
We veri®ed whether this partial rescue of enzymatic activity was biologically signi®cant by carrying out a focus forming assay in NIH3T3 cells with the same set of Tpr-Met mutants previously tested biochemically. Table 2 shows that, as expected, the Y?F Tpr-Met mutant was completely inactive in the transformation assay (Y?F column in Tpr-Met wild type row). However the Y?F Tpr-Met construct bearing the M1268T mutation possessed residual transforming . Labeled proteins were resolved by SDS ± PAGE on an 8% gel. Dried gels were subjected to autoradiography. Immunoprecipitates were obtained from lysates normalized for Tpr-Met content by Western blot (lower parts in a and b). Lane 1: mock-transfected COS-1 cells. Even lanes (2 ± 10): constructs with wild type A-loop. Odd lanes (3 ± 11): constructs with Y1252-1253F mutations in A-loop Table 2 Transforming activity of Tpr-Met mutants
Results are expressed as percentage of focus forming ability relative to Tpr-Met (100%). Tpr-Met yields approx. 150 foci/10 mg of cDNA in this assay activity (approximately 10% of the control). This partial rescue did not occur with the D1246H/N mutations.
Column Y in Table 2 shows that the transforming eciency of Tpr-Met was increased not only by the M1268T but also by the two naturally occurring D1246H/N mutations. This indicates that the eect of both mutations was biologically detectable on a background of Tpr-mediated dimerization. Interestingly, the D?V mutation, not found in human tumors, did not enhance Tpr-Met-mediated transformation.
The D1246H/N (but not the M1268T) mutations promote activation of the isolated Met kinase domain Figure 3 and Table 3 show the results obtained by testing the mutations considered above within a dimerization-free Cyto-Met molecule. Figure 3a shows that immunoprecipitates of CytoMet, either in the wild-type form or bearing the M1268T mutation, were inactive in an in vitro kinase assay (lanes 3 and 5). Conversely, in the presence of the three D1246H/N/V mutations, the Cyto-Met constructs were capable of autophosphorylation (lanes 7, 9, 11). The same was true in the case of transphosphorylation of the exogenous substrate MBP (see Figure 3b ). Immunoprecipitation with a divalent antibody might contribute to activation of the mutated Cyto-Met proteins. To verify whether the D1246H/N/V CytoMet are indeed active (tyrosine-phosphorylated) in vivo, protein extracts of COS-1 cells expressing these constructs were directly probed with an anti-phosphotyrosine antibody. Figure 3c shows that Cyto-Met carrying either of the two naturally occurring D1246H/ N mutations was highly phosphorylated in vivo (lanes 7 and 9), as compared with Tpr-Met (lane 2). The D?V version of Cyto-Met (lane 11) showed a lower level of phosphorylation. Wild type and M1268T Cyto-Met (lanes 3 and 5) were barely detectable with this antibody. Thus the naturally occurring D1246H/N mutations also promoted constitutive activation of Cyto-Met in vivo, in an antibody-independent way.
To verify their biological activity we tested the CytoMet constructs in a focus forming assay. While the wild type and M1268T constructs were non-transforming, the D1246H/N/V Cyto-Met constructs (especially those bearing the two naturally occurring mutations) caused the appearance of a signi®cant number of foci (approximately 10% of the corresponding Tpr-Met, Table 3 ). These results indicate that in spite of the lack of a dimerizing moiety and of their cytoplasmic localization, the D1246H/N/V Cyto-Met mutants are active and capable of generating a signal sucient to transform NIH3T3 cells, albeit at low eciency.
The D1246H/N (but not the M1268T) Met mutants have a reduced requirement for HGF in transformation
The results described above with the Cyto-Met constructs prompted us to verify whether a dierence between the mechanism of activation of the D1246H/N and the M1268T mutations could be demonstrated also in the full-size Met molecule. In a biological approach, we tested the transforming activity of the wild type, M1268T and D1246H/N/V Met receptors with or without exogenous HGF (using a sub-clone of NIH3T3 cells negative for endogenous HGF). Figure 4 shows that, in line with the recent report by Michieli et al. (1999) , none of the mutants was transforming in the absence of exogenous HGF. This indicates that the D1246H/N/V mutations were not sucient per se to activate the full-size receptor. However, when the focus forming assay was done in the presence of limiting concentrations of recombinant HGF, the two naturally occurring D1246H/N Met mutants (and to a lesser extent the D1246V mutant) produced a signi®cant number of foci even at the lowest concentration, while the wild type and the M1268T Met receptors required a higher amount of HGF to transform.
All A-loop mutations share the same mechanism of action Since the Cyto-Met constructs had proved useful to unravel a dierence in the mechanism of activation of the D1246H/N versus the M1268T mutation, we inserted in Cyto-Met all the missense mutations described in hereditary papillary renal carcinoma (HPRC) by Schmidt et al. (1997) and in hepatocellular carcinoma (HCC) by Park et al. (1999) . Additional mutations located in the N-terminal lobe, successively found in sporadic papillary renal carcinoma (PRC) (Schmidt et al., 1999) were not included in this study. The upper part of Figure 5 shows a Western blot of protein extracts obtained from COS-1 cells transfected with these constructs, probed with an anti-PTyr antibody. Three HPRC and one HCC mutations (V1238I, Y1248C, Y1248H: lanes 7, 8, 9 and 
Discussion
Recent studies have identi®ed a series of point mutations in the Met kinase in hereditary and sporadic papillary renal carcinomas and in a few cases of childhood hepatocellular carcinoma (Schmidt et al., 1997 (Schmidt et al., , 1999 Park et al., 1999) . Altogether twelve dierent residues (all located in the kinase domain, four in the N-terminal and eight in the C-terminal lobe) when mutated, can confer on the receptor the ability to transform rodent ®broblasts, apparently by increasing its catalytic activity (Jeers et al., 1997; Bardelli et al., 1998) .
Two of the aminoacid substitutions involve conserved residues (D1246 and M1268) previously found mutated in tumorigenic versions of Ret and Kit. D1246 is located right in the middle of the A-loop. M1268 is in the P+1 loop and contributes to recognition of the residue in position +3 to the tyrosine in peptide substrates (Songyang et al., 1995) . Substitution of M918 with T alters phosphorylation of the Ret receptor and of its substrates in vivo (Liu et al., 1996) . Subversion of speci®city has also been observed for the M1268T Met mutant using synthetic peptides (Bardelli et al., 1998) . However, for Met, evidence of aberrant phosphorylation in vivo is still lacking.
The activating eect of both mutations could be related to the ability to relieve auto-inhibition of the unstimulated receptor. Structural data are not yet available for Met, but a 40% sequence identitity with the insulin receptor kinase (IRK) and the presence of a conserved tyrosine triad (Y1158 and Y1162-1163 in IRK; Y1248 and Y1252-1253 in Met) in the A-loop of both receptors, suggest that the IRK structure can be used to model Met with good approximation (Schmidt et al., 1999) . In unphosphorylated IRK the ®rst of the tandem A-loop tyrosines, Y1162, is directly engaged into the catalytic pocket and the A-loop inhibits enzymatic activity by blocking access to the active site (Hubbard et al., 1994) . Insulin-triggered transphosphorylation of the three tyrosine residues shifts the Aloop to a permissive conformation. This is stabilized by bridging of PTyr 1162 via a hydrogen bond to highly conserved Arg 1155 (Hubbard et al., 1997) . The aspartic acid mutated in oncogenic Kit (D816) and Met (D1246) lies next to the conserved arginine. In IRK, the active conformation is further stabilized by two hydrogen bonds between the phosphate group of PTyr 1163 and the side chain of Arg 1164 (Hubbard et al., 1997) . Interestingly an Arg or a Lys residue is found at this position in all RTKs with tandem A-loop tyrosines, except Met. This suggests that, compared to IRK, the active form of Met may lack an element of stabilization.
In the unphosphorylated FGF receptor 1 kinase (FGFR1K) the inhibitory mechanism does not involve an A-loop tyrosine, like in IRK. Rather, Arg 661 (lying at the carboxy-terminal end of the A-loop) and the invariant Pro 663 (found in the P+1 loop) block the substrate pocket (Mohammadi et al., 1996) . Met, like FGFR1, has a positively charged aminoacid (Lys1262) in the position corresponding to Arg 661, while all other RTKs with tandem A-loop tyrosines have a hydrophobic residue. Thus the mechanism of Met auto-inhibition may share some features with IRK and some with FGFR1.
Given their location, both mutations could interfere with Met self-inhibition by disengaging the A-loop from the active site and by making the substrate pocket more accessible. This work was designed to explore these possibilities, and to ®nd out whether the activating eect of the two mutations is based on a common molecular mechanism.
The M1268T and D1246H/N mutations were tested alone or in combination with Y?F substitutions of the tandem A-loop tyrosines. The M?T mutation, previously tested in combination with Y?F mutations in Ret and Met, appeared to rescue the kinase activity of the former but not of the latter (Iwashita et al., 1996; Jeers et al., 1998b) . To verify the possible concurrent eect of dimerization we tested the mutations within the fully dimerized Tpr-Met molecule or within the dimerization-free Met moiety of Tpr-Met (Cyto-Met), rather than in the full size receptor.
In Tpr-Met the M1268T and the D1246H/N mutations had distinct eects in combination with Y?F mutation of the A-loop tyrosines. In fact M1268T rescued (at least in part) the ability of the Y?F mutant to transphosphorylate an exogenous substrate, while D1246H/N did not. This result suggests that the M1268T mutation may act by partially dislodging the activation loop from the active site and by increasing accessibility of the substratebinding pocket. The M1268T mutation, however, requires dimerization to exert its eect. It has been shown that combining this mutation with the substitu- Aloop and P+1 loop: KV 1238 ADFGLARD 1246 MY 1248 D-KEYYSVHNKTGAK 1262 LPVKWM 1268 A. Aminoacids are numbered according to Schmidt et al. (1999) tion of another highly conserved residue (L1213V) essentially abrogates ligand dependency, at least in a chimeric Trk-Met construct (Jeers and Vande Woude, 1999) . It should be noted, however, that the two mutations are never found together in naturally occurring tumors.
The lack of activity of the wild type and M1268T Cyto-Met constructs con®rmed their complete dependence on dimerization. However, surprisingly, the D1246H/N Cyto-Met constructs were active, both in kinase assay and in terms of their phosphorylation in vivo. These mutants could also transform rodent ®broblasts, implying phosphorylation not only of the A-loop tyrosines, but also of the carboxy-terminal tyrosines essential for signaling. The absence of a dimerization motif suggests that the mutations may confer to the Met kinase the ability to autophosphorylate in cis. However, given the current working model for RTK activation (cis-inhibition/ trans-activation, Hubbard et al., 1998) , the likelihood of cis-activation seems remote. A simpler explanation would be that these mutations may increase accessibility of the A-loop tyrosines for trans-autophosphorylation and contribute to the stability of its noninhibitory conformation.
It was of interest to verify whether this eect, observed in a construct free from the inhibitory constraints imposed by the extra-cellular domain, could also be demonstrated in the full-size receptor. To this end we tested the trasforming ability of the full size M1268T and D1246H/N Met receptors adding limiting amounts of HGF. In our conditions none of the mutants showed any transforming ability in the absence of the ligand (see also Michieli et al., 1999) . However, the D1246H/N mutants began to induce transformation at HGF concentrations three to nine times lower than that required for wild type Met or for the M1268T mutant. This result is consistent with the explanation proposed above.
An alternative interpretation for these results and for those obtained with Cyto-Met is suggested by recent advances on the D814Y mutation in c-Kit. Two reports indicate that this mutation may promote dimerization of the Kit kinase from the cytoplasmic side of the molecule. A ®rst study shows that the soluble tyrosine kinase domain of c-Kit bearing the D814Y mutation migrates as a dimer upon a gel ®ltration column, while its wild type counterpart migrates as a monomer (Lam et al., 1999) . A second study shows that mutation of the D814 codon causes activation by promoting Kit receptor selfassociation without dimerization of the extra-cellular domain (Tsujimura et al., 1999) . Whether mutation of the conserved Asp residue induces dimerization of the isolated Met kinase domain as well, remains to be demonstrated. Moreover, the D?V/Y mutation is fully activating in Kit, while D?H/N is still ligand-dependent in Met. Recent results in other systems, such as the erythropoietin receptor and the Erb2/neu RTK, suggest that while dimerization is required, it may not be always sucient for receptor activation (Jiang and Hunter, 1999) .
Regardless of the details of its mode of action, the eect of the D1246H/N mutation could be unique or be shared by other activating mutations located in the A-loop. In our last experiment we tested in Cyto-Met all the activating mutations located in the carboxyterminal lobe of the Met kinase (plus one in the Nterminal lobe). Interestingly, we found other mutations capable of inducing phosphorylation of the isolated Met kinase domain, all located in the A-loop. Some of these substitutions converted residues unique to Met (V1238, K1262) in those present in the wild type form of the Ret or Kit receptors (I or R, respectively), again con®rming the subtle dierences among RTKs.
This study establishes that there is a dierence in the mechanism of activation of two point mutations present in tumorigenic forms of Ret, Kit, and Met, and potentially involved in the oncogenic activation of other RTKs. The M1268T mutation (which changes a residue in the P+1 loop) may interfere with the mechanism of auto-inhibition of RTKs by increasing accessibility of the substrate-binding pocket and/or by partially displacing the A-loop from the active site. This eect in Met is completely dependent on ligandinduced dimerization. The D1246H/N mutation, located in the middle of the A-loop, renders the Met receptor less dependent on the ligand, most likely by increasing accessibility of A-loop tyrosines to transphosphorylation or by stabilizing its non-inhibited conformation. The eect of this mutation is mimicked by other substitutions, all involving residues located in the A-loop.
These data highlight the importance of HGF in unmasking the oncogenic activity of the mutated forms of Met, and con®rm the validity of devising HGFdirected therapeutic strategies for cancer treatment. On the other hand, they suggest that the oncogenic form of the Met receptor bearing the M1268T mutation in the P+1 loop could be more sensitive to substrate-analog inhibitors than the wild-type or the D1246H/N mutant receptor.
Materials and methods
Reagents, cells and antibodies
All reagents, unless speci®ed, were from Sigma Chemical Co. Protein A Sepharose CL-4B was from Amersham/Pharmacia Biotech. Inc. Radioactive isotopes were from ICN Biomedicals. COS-1 cells (from American Type Culture Collection) were cultured in DMEM medium supplemented with 10% FCS (Gibco, Inc.) in a 5% CO 2 -water-saturated atmosphere. NIH3T3 cells (a gift from G Gaudino, Amedeo Avogadro University, Novara) were cultured in DMEM medium supplemented with 10% heat-inactivated calf serum (Gibco, Inc). Polyclonal anti-human Met (C-12; #sc-10) and monoclonal anti-PTyr (PY-99: #sc-7020) antibodies were from Santa Cruz Biotechnology, Inc. Recombinant HGF (Naldini et al., 1995) was produced in baculovirus-infected cells and puri®ed as described by Yee et al. (1993) .
Cloning and mutagenesis of cDNA constructs
Cloning of the full-size MET and TPR-MET cDNAs has been previously reported (Ponzetto et al., 1991 (Ponzetto et al., , 1994 . To generate the recombinant Cyto-MET construct, the cDNA sequence coding for aminoacids 1028 ± 1408 (corresponding to the Met moiety in Tpr-Met, see Park et al., 1987) was ampli®ed by PCR using a 5' primer containing a PstI restriction site and a 3' primer containing an EcoRI restriction site. The PCR product was digested with PstI and EcoRI and inserted into the pMT2 expression vector. The M1268T and D1246H/N mutations were generated using wild type constructs (coding for full-size Met, Tpr-Met, or Cyto-Met) as templates. A QuickChange site-directed mutagenesis kit (Stratagene) was used for all mutagenesis following manufacturer's instructions. Mutations were veri®ed by sequencing the region of interest, using an AmpliCycle sequencing kit from Perkin Elmer/Roche Molecular Systems, Inc.
Expression of cDNA constructs
Transfections in COS-1 cells were performed using subconuent cells growing in the presence of 10% fetal calf serum (5610 5 to 1610 6 cells per 100 mm diameter culture dishes). Cells were transfected with 10 mg of cDNA in the pMT2 vector using the Calcium Phosphate Precipitation Transfection System (Pharmacia) according to the manufacturer's protocol. Empty vector was used in control experiments. Cells were lysed 48 h after transfection.
Immunoprecipitation and Western blotting
Transfected COS-1 cells were lysed with EB buer (10 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100) supplemented with a cocktail of protease inhibitors (pepstatin, leupeptin, aprotinin) and 1 mM PMSF. For Western blot analysis, 1 mM sodium orthovanadate was added to the lysis buer. Lysates were normalized for TprMet or Cyto-Met content by Western blot with anti-Met antibody. For immunoprecipitation, normalized lysates were incubated with 2 mg/ml of anti-human Met and 30 ml of packed Protein A Sepharose beads for 2 h at 48C. Beads were collected by centrifugation, washed three times with EB buer and used for kinase assays.
In vitro kinase assay
Immunocomplexes prepared as described above were washed once with kinase buer (KB: 50 mM HEPES pH 7.5, 150 mM NaCl, 12.5 mM MgCl 2 ) and incubated in 50 ml of KB in the presence of 10 mCi of [g-32 P]ATP. The reaction was carried out at 258C for 15 min, and stopped by adding 1 ml of cold EB buer. After two washes with EB buer, concentrated Laemmli buer was added to the beads and samples were heated for 10 min at 958C. The eluted proteins were subjected to SDS ± PAGE. The radioactive gel was dried and the signal was detected by autoradiography. The experiments shown are representative of results obtained at least three times.
MBP kinase assay
Phosphorylation of myelin basic protein (MBP) was performed using the above immuno-precipitates as previously reported (Ponzetto et al., 1994) .
Focus forming assay
NIH3T3 cells (one 100 mm dish at 60% con¯uence) were cotransfected with 10 mg of the indicated cDNA and 1 mg of pSV2Neo. Two days after transfection cells were split 1 : 5 and kept in DMEM medium with 10% heat-inactivated serum. The medium was changed every 3 days. Cells in one of the ®ve plates were selected with G418 (700 mg/ml). Counts of Met positive clones were used to evaluate the eciency of transfection. Transformed foci in the other four plates were counted after 3 weeks. In the focus forming assay performed using full-size Met cDNAs with the addition of recombinant HGF, foci were counted 4 weeks after transfection.
